Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in its Phase 2 study evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.
The trial enrolled 325 patients already on a stable course of an antipsychotic medication that were randomized to receive 1 gm, 2 gm or 4 gm of CTP-692 or placebo once-daily. The primary outcome measure is the change in the positive and negative syndrome scale total score at 12 weeks compared to baseline.
“CTP-692 offers a potential new mechanism to treat schizophrenia that, when combined with existing antipsychotic medications, may more broadly address disease symptoms than is currently possible,” James Cassella, Concert’s chief development officer, said in a statement.
“We designed the Phase 2 study to assess CTP-692’s potential to improve on the primary symptom domains in schizophrenia, including positive and negative symptoms and cognitive function, when added to existing antipsychotic treatments,” he added.
Concert expects to report topline data from the trial in the first quarter of 2021.
